Stifel Financial Corp Sells 2,700 Shares of COMPASS Pathways plc (NASDAQ:CMPS)

Stifel Financial Corp lessened its holdings in shares of COMPASS Pathways plc (NASDAQ:CMPS) by 7.2% in the third quarter, Holdings Channel.com reports. The firm owned 34,700 shares of the company’s stock after selling 2,700 shares during the period. Stifel Financial Corp’s holdings in COMPASS Pathways were worth $219,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also recently modified their holdings of the business. Point72 Asset Management L.P. purchased a new stake in shares of COMPASS Pathways during the 3rd quarter valued at approximately $371,000. Polar Asset Management Partners Inc. lifted its position in shares of COMPASS Pathways by 83.3% during the third quarter. Polar Asset Management Partners Inc. now owns 567,600 shares of the company’s stock worth $3,576,000 after acquiring an additional 258,000 shares in the last quarter. Sio Capital Management LLC lifted its position in shares of COMPASS Pathways by 211.7% during the third quarter. Sio Capital Management LLC now owns 914,639 shares of the company’s stock worth $5,762,000 after acquiring an additional 621,222 shares in the last quarter. Walleye Capital LLC bought a new position in shares of COMPASS Pathways in the third quarter worth $2,126,000. Finally, Acuta Capital Partners LLC purchased a new position in shares of COMPASS Pathways in the third quarter valued at $2,435,000. Hedge funds and other institutional investors own 46.19% of the company’s stock.

COMPASS Pathways Stock Performance

NASDAQ:CMPS opened at $3.99 on Monday. The stock has a market cap of $273.00 million, a P/E ratio of -1.81 and a beta of 2.24. The company has a quick ratio of 8.91, a current ratio of 8.91 and a debt-to-equity ratio of 0.15. The business’s 50-day moving average price is $4.81 and its two-hundred day moving average price is $6.10. COMPASS Pathways plc has a twelve month low of $3.86 and a twelve month high of $12.75.

COMPASS Pathways (NASDAQ:CMPS) last announced its earnings results on Thursday, October 31st. The company reported ($0.56) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.60) by $0.04. During the same quarter in the previous year, the company earned ($0.67) earnings per share. As a group, equities analysts predict that COMPASS Pathways plc will post -2.33 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on the company. HC Wainwright dropped their price objective on COMPASS Pathways from $120.00 to $60.00 and set a “buy” rating on the stock in a report on Friday, November 1st. Cantor Fitzgerald reissued an “overweight” rating on shares of COMPASS Pathways in a report on Monday, September 9th. Royal Bank of Canada reduced their price objective on shares of COMPASS Pathways from $23.00 to $18.00 and set an “outperform” rating for the company in a research note on Friday, November 1st. Finally, Maxim Group decreased their target price on shares of COMPASS Pathways from $22.00 to $12.00 and set a “buy” rating on the stock in a report on Friday, November 1st. Six analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $33.60.

COMPASS Pathways Company Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.